In the past week, SBS stock has gone up by 9.20%, with a monthly gain of 2.65% and a quarterly surge of 21.93%. The volatility ratio for the week is 2.71%, and the volatility levels for the last 30 days are 2.19% for Companhia de Saneamento Basico do Estado de Sao Paulo. ADR The simple moving average for the past 20 days is 7.41% for SBS’s stock, with a 13.06% simple moving average for the past 200 days.
Is It Worth Investing in Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (NYSE: SBS) Right Now?
Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (NYSE: SBS) has a higher price-to-earnings ratio of 7.07x compared to its average ratio. SBS has 36-month beta value of 0.78. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SBS is 683.42M, and currently, short sellers hold a 0.73% ratio of that float. The average trading volume of SBS on March 19, 2025 was 780.41K shares.
SBS) stock’s latest price update
The stock of Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (NYSE: SBS) has increased by 2.25 when compared to last closing price of 17.59.Despite this, the company has seen a gain of 9.20% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-19 that This study, initiated yesterday, is one of five clinical efforts – three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies – of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regions Availability of first IIT proof-of-concept results potentially in H1 2025 Crofelemer, Jaguar’s novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both SBS-IF and MVID SAN FRANCISCO, CA / ACCESS Newswire / February 19, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) family companies Napo Pharmaceuticals (“Napo”) and Napo Therapeutics today announced that the clinical protocol for Napo’s Phase 2 study to evaluate the efficacy of crofelemer, Jaguar’s novel plant-based anti-secretory prescription drug, for the indication of SBS-IF in adults has received regulatory clearance from health authorities in Italy and Germany, where the trial will be conducted. The study initiated yesterday, February 18, 2025.
SBS Trading at 10.43% from the 50-Day Moving Average
After a stumble in the market that brought SBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.04% of loss for the given period.
Volatility was left at 2.19%, however, over the last 30 days, the volatility rate increased by 2.71%, as shares surge +5.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.53% upper at present.
During the last 5 trading sessions, SBS rose by +9.96%, which changed the moving average for the period of 200-days by +25.85% in comparison to the 20-day moving average, which settled at $16.75. In addition, Companhia de Saneamento Basico do Estado de Sao Paulo. ADR saw 25.51% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SBS
Current profitability levels for the company are sitting at:
- 0.45 for the present operating margin
- 0.7 for the gross margin
The net margin for Companhia de Saneamento Basico do Estado de Sao Paulo. ADR stands at 0.26. The total capital return value is set at 0.23. Equity return is now at value 27.03, with 13.34 for asset returns.
Based on Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (SBS), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 0.63. The interest coverage ratio of the stock is 11.36.
Currently, EBITDA for the company is 8.96 billion with net debt to EBITDA at 1.14. When we switch over and look at the enterprise to sales, we see a ratio of 2.57. The receivables turnover for the company is 8.67for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.14.
Conclusion
To put it simply, Companhia de Saneamento Basico do Estado de Sao Paulo. ADR (SBS) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
